Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies, announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported a cash balance of $295.1 million, which is expected to fund operations into 2029. For the fourth quarter of 2025, Nkarta incurred a net loss of $27.4 million, or $0.37 per share, while the total net loss for the full year was $104.1 million, or $1.41 per share. Research and development expenses for the year were $90.4 million, with $25.3 million incurred in the fourth quarter. General and administrative expenses totaled $31.6 million for the year, with $5.7 million in the fourth quarter. The company is advancing its NKX019 clinical program, with dose escalation now reaching 4 billion cells per dose. Initial clinical data from the Ntrust-1 and Ntrust-2 trials is expected to be presented at a medical conference in 2026. Nkarta's CEO, Paul J. Hastings, emphasized the strategic importance of 2025, highlighting the onboarding of a clinical team with deep autoimmune experience and the ongoing enrollment in clinical trials. The company remains focused on disciplined clinical execution as it continues to advance its CAR-NK cell therapy platform.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.